Overview

Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms

Status:
Enrolling by invitation
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Coversin in Paroxysmal Nocturnal Hemoglobinuria (PNH) in patients with resistance to Eculizumab due to complement C5 polymorphisms.
Phase:
Phase 2
Details
Lead Sponsor:
AKARI Therapeutics
Treatments:
Complement C5
Complement System Proteins